Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue

Share:
Related MYL
Mylan Unveils Generic Avodart Capsules
Argus Sees Perrigo Going Lower After CEO Exit, Guidance Cut
Related SLXP
BMO Still Believes Valeant Is Undervalued
Benzinga's Volume Movers

Below are the top drugs-generic stocks on the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Mylan (NASDAQ: MYL) is $6.39 billion. Mylan's ROA for the same period is 5.89%.

The trailing-twelve-month revenue at Salix Pharmaceuticals Ltd (NASDAQ: SLXP) is $605.72 million. Salix Pharmaceuticals had $665.87 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Hi Tech Pharmacal Co (NASDAQ: HITK) is $230.00 million. Hi Tech Pharmacal's ROE for the same period is 23.17%.

The trailing-twelve-month revenue at Akorn (NASDAQ: AKRX) is $163.19 million. Akorn's operating margin for the same period is 26.68%.

Posted-In: Drugs-Generic Industry Highest Revenue NASDAQTrading Ideas

 

Related Articles (AKRX + HITK)

View Comments and Join the Discussion!